A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis

Journal of Medicinal Chemistry

Volumn 59, Issue 1, 2016, Pages 132-146

  Bold, Guido ^a   Schnell, Christian ^a   Furet, Pascal ^a   McSheehy, Paul ^a   Brüggen, Josef ^a   Mestan, Jürgen ^a   Manley, Paul W ^a   Drückes, Peter ^a   Burglin, Marion ^a   Dürler, Ursula ^a   Loretan, Jacqueline ^a   Reuter, Robert ^a   Wartmann, Markus ^a   Theuer, Andreas ^a   Bauer Probst, Beatrice ^a   Martiny Baron, Georg ^a   Allegrini, Peter ^a   Goepfert, Arnaud ^a   Wood, Jeanette ^a   Littlewood Evans, Amanda ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2 AMINO 6 CHLORO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID; 6 (2 AMINO 6 CHLORO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID(3 TRIFLUOROMETHYL PHENYL)AMIDE; 6 (2 AMINO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID; 6 (2 AMINO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID(3 TRIFLUOROMETHYL PHENYL)AMIDE; 6 (2 AMINO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID(4 FLUORO 3 TRIFLUOROMETHYL PHENYL)AMIDE; 6 (2 AMINO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID[4 (4 METHYL PIPERAZIN 1 YLMETHYL) 3 TRIFLUOROMETHYL PHENYL]AMIDE; 6 (6 AMINO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID; 6 (6 AMINO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID(3 ETHYL PHENYL)AMIDE; 6 (6 AMINO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID(3 TRIFLUOROMETHYL PHENYL)AMIDE; 6 (6 AMINO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID(4 FLUORO 3 TRIFLUOROMETHYL PHENYL)AMIDE; 6 (6 CHLORO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID; 6 (6 CHOLRO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID(3 TRIFLUOROMETHYL PHENYL)AMIDE; 6 (6 CYANO PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID(3 TRIFLUOROMETHYL PHENYL)AMIDE; 6 (6 HYDROXYMETHYL PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXYLIC ACID (3 TRIFLUOROMETHYL PHENYL)AMIDE; 6 (PYRIMIDIN 4 YLOXY)NAPHTHALENE 1 CARBOXAMIDE DERIVATIVE; 6 [5 (3 TRIFLUOROMETHYL PHENYLCARBAMOYL)NAPHTHALEN 2 YLOXY]PYRIMIDINE 4 CARBOXYLIC ACID ETHYL ESTER; AAL 993; ANGIOPOIETIN RECEPTOR; ORANTINIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VATALANIB; [4 [5 (4 FLUORO 3 TRIFLUOROMETHYL PHENYLCARBAMOYL)NAPHTHALEN 2 YLOXY]PYRIMIDIN 2 YL]CARBAMIC ACID METHYL ESTER; ANGIOGENESIS INHIBITOR; PROTEIN KINASE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMICAL ANALYSIS; BREAST CARCINOMA; CANCER INHIBITION; CHEMICAL ANALYSIS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MOUSE; NONHUMAN; RAT; RODENT; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; DRUG SCREENING; FEMALE; HAMSTER; MELANOMA, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MODELS, MOLECULAR; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955124287     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01582     Document Type: Article

References (42)

1. Carmeliet, P. Angiogenesis in health and disease Nat. Med. 2003, 9, 653-660 10.1038/nm0603-653
2. Plate, K. H.; Breier, G.; Weich, H. A.; Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo Nature 1992, 359, 845-848 10.1038/359845a0
3. Senger, D. R.; Van de Water, L.; Brown, L. F.; Nagy, J. A.; Yeo, K. T.; Yeo, T. K.; Berse, B.; Jackman, R. W.; Dvorak, A. M.; Dvorak, H. F. Vascular permeability factor (VPF, VEGF) in tumor biology Cancer Metastasis Rev. 1993, 12, 303-324 10.1007/BF00665960
4. Carmeliet, P.; Ferreira, V.; Breier, G.; Pollefeyt, S.; Kieckens, L.; Gertsenstein, M.; Fahrig, M.; Vandenhoeck, A.; Harpal, K.; Eberhardt, C.; Declercq, C.; Pawling, J.; Moons, L.; Collen, D.; Risau, W.; Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele Nature 1996, 380, 435-439 10.1038/380435a0
5. Klagsbrun, M.; D'Amore, P. A. Vascular endothelial growth factor and its receptors Cytokine Growth Factor Rev. 1996, 7, 259-270 10.1016/S1359-6101(96)00027-5
6. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease Nat. Med. 1995, 1, 27-31 10.1038/nm0195-27
7. Folkman, J. Tumor angiogenesis Adv. Cancer Res. 1985, 43, 175-203 10.1016/S0065-230X(08)60946-X
8. Folkman, J. The role of angiogenesis in tumor growth Semin. Cancer Biol. 1992, 3, 65-71
9. Plate, K. H.; Breier, G.; Risau, W. Molecular mechanisms of developmental and tumor angiogenesis Brain Pathol. 1994, 4, 207-218 10.1111/j.1750-3639.1994.tb00835.x
10. Martiny-Baron, G.; Marmé, D. VEGF-mediated tumour angiogenesis: a new target for cancer therapy Curr. Opin. Biotechnol. 1995, 6, 675-680 10.1016/0958-1669(95)80111-1
11. Liotta, L. A.; Steeg, P. S.; Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation Cell 1991, 64, 327-336 10.1016/0092-8674(91)90642-C
12. Parangi, S.; O'Reilly, M.; Christofori, G.; Holmgren, L.; Grosfeld, J.; Folkman, J.; Hanahan, D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 2002-2007 10.1073/pnas.93.5.2002
13. Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors Ann. Surg. 1972, 175, 409-416 10.1097/00000658-197203000-00014
14. Sitohy, B.; Nagy, J. A.; Dvorak, H. F. Anti-VEGF/VEGFR therapy for cancer: reassessing the target Cancer Res. 2012, 72, 1909-1914 10.1158/0008-5472.CAN-11-3406
15. Musumeci, F.; Radi, M.; Brullo, C.; Schenone, S. Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors J. Med. Chem. 2012, 55, 10797-10822 10.1021/jm301085w
16. Zhang, C.; Tan, C.; Ding, H.; Xin, T.; Jiang, Y. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials Curr. Pharm. Des. 2012, 18, 2921-2935 10.2174/138161212800672732
17. Bold, G.; Altmann, K. H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Brüggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rösel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lässer, R.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyss, D.; Wood, J. M. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis J. Med. Chem. 2000, 43, 2310-2323 10.1021/jm9909443
18. ibid. 2000, 43, 3200.
19. Manley, P. W.; Furet, P.; Bold, G.; Brüggen, J.; Mestan, J.; Meyer, T.; Schnell, C.; Wood, J.; Haberey, M.; Huth, A.; Krüger, M.; Menrad, A.; Ottow, E.; Seidelmann, D.; Siemeister, G.; Thierauch, K. H. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors J. Med. Chem. 2002, 45, 5687-5693 10.1021/jm020899q
20. Potashman, M.; Kim, T.; Bellon, S.; Booker, S.; Cheng, Y.; Kim, J. L.; Tasker, A.; Xi, N.; Xu, S.; Harmange, J. C.; Borg, G.; Weiss, M.; Hodous, B. L.; Graceffa, R.; Buckner, W. H.; Masse, C. E.; Choquette, D.; Martin, M. W.; Germain, J.; Dipietro, L. V.; Chaffee, S. C.; Nunes, J. J.; Buchanan, J. L.; Habgood, G. J.; McGowan, D. C.; Whittington, D. A. Compounds and methods of use. WO 2005/070891, 2005.
21. Bold, G.; Capraro, H. G.; Caravatti, G.; Flörsheimer, A.; Furet, P.; Manley, P. W.; Vaupel, A.; Pissot-Soldermann, C.; Gessier, F.; Schnell, C.; Littlewood-Evans, A. J.; Kapa, P. K.; Bajwa, J. S.; Jiang, X. Bicyclic amides as kinase inhibitors. WO 2006/059234, 2006. Biological activities of two of the compounds were described in
22. Halin, C.; Fahrngruber, H.; Meingassner, J. G.; Bold, G.; Littlewood-Evans, A.; Stütz, A.; Detmar, M. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor Am. J. Pathol. 2008, 173, 265-277 10.2353/ajpath.2008.071074
23. Meingassner, J. G.; Fahrngruber, H.; Kowalsky, E.; Billich, A.; Bold, G.; Littlewood-Evans, A.; Stütz, A. NVP-BFH772, a potent inhibitor of VEGF receptor tyrosine kinases, is effective in models of skin inflammation J. Invest. Dermatol. 2011, 131, 480
24. Shieh, W. C.; McKenna, J.; Sclafani, J. A.; Xue, S.; Girgis, M.; Vivelo, J.; Radetich, B.; Prasad, K. Syntheses of a triad of Flt3 kinase inhibitors: from bench to pilot plant Org. Process Res. Dev. 2008, 12, 1146-1155 10.1021/op800136f
25. Weisberg, E.; Rösel, J.; Bold, G.; Furet, P.; Jiang, J.; Cools, J.; Wright, R. D.; Nelson, E.; Barrett, R.; Ray, A.; Moreno, D.; Hall-Meyers, E.; Stone, R.; Galinsky, I.; Fox, E.; Gilliland, G.; Daley, J. F.; Lazo-Kallanian, S.; Kung, A. L.; Griffin, J. D. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells Blood 2008, 112, 5161-5170 10.1182/blood-2008-02-138065
26. Akeno-Stuart, N.; Croyle, M.; Knauf, J. A.; Malaguarnera, R.; Vitagliano, D.; Santoro, M.; Stephan, C.; Grosios, K.; Wartmann, M.; Cozens, R.; Caravatti, G.; Fabbro, D.; Lane, H. A.; Fagin, J. A. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells Cancer Res. 2007, 67, 6956-6964 10.1158/0008-5472.CAN-06-4605
27. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rösel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K. H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F.; Marmé, D. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res. 2000, 60, 2178-2189
28. Manley, P. W.; Bold, G.; Brüggen, J.; Fendrich, G.; Furet, P.; Mestan, J.; Schnell, C.; Stolz, B.; Meyer, T.; Meyhack, B.; Stark, W.; Strauss, A.; Wood, J. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis Biochim. Biophys. Acta, Proteins Proteomics 2004, 1697, 17-27 10.1016/j.bbapap.2003.11.010
29. At the time this work was accomplished, there was no crystal structure of the FLT3 kinase in the "DFG out" conformation available. We resorted to a homology model described in: Weisberg, E.; Rösel, J.; Furet, P.; Bold, G.; Imbach, P.; Flörsheimer, A.; Caravatti, G.; Jiang, J.; Manley, P. W.; Ray, A.; Griffin, J. D. Antileukemic effects of novel first-and second-generation FLT3 inhibitors: structure-affinity comparison Genes Cancer 2010, 1, 1021-1032 10.1177/1947601910396505
30. Warmuth, M.; Kim, S.; Gu, X. J.; Xia, G.; Adrián, F. Ba/F3 cells and their use in kinase drug discovery Curr. Opin. Oncol. 2007, 19, 55-60 10.1097/CCO.0b013e328011a25f
31. Buchdunger, E.; Trinks, U.; Mett, H.; Regenass, U.; Müller, M.; Meyer, T.; McGlynn, E.; Pinna, L. A.; Traxler, P.; Lydon, N. B. 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 2334-2338 10.1073/pnas.91.6.2334
32. LaMontagne, K.; Littlewood-Evans, A.; Schnell, C.; O'Reilly, T.; Wyder, L.; Sanchez, T.; Probst, B.; Butler, J.; Wood, A.; Liau, G.; Billy, E.; Theuer, A.; Hla, T.; Wood, J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization Cancer Res. 2006, 66, 221-231 10.1158/0008-5472.CAN-05-2001
33. Weidensteiner, C.; Rausch, M.; McSheehy, P.M. J.; Allegrini, P. R. Quantitative dynamic contrast-enhanced MRI in tumor-bearing rats and mice with inversion recovery TrueFISP and two contrast agents at 4.7 T Journal of Magnetic Resonance Imaging 2006, 24, 646-656 10.1002/jmri.20676
34. Moss, A. The angiopoietin:Tie 2 interaction: a potential target for future therapies in human vascular disease Cytokine Growth Factor Rev. 2013, 24, 579-592 10.1016/j.cytogfr.2013.05.009
35. Fallahi, P.; Mazzi, V.; Vita, R.; Ferrari, S. M.; Materazzi, G.; Galleri, D.; Benvenga, S.; Miccoli, P.; Antonelli, A. New therapies for dedifferentiated papillary thyroid cancer Int. J. Mol. Sci. 2015, 16, 6153-6182 10.3390/ijms16036153
36. Ravegnini, G.; Nannini, M.; Sammarini, G.; Astolfi, A.; Biasco, G.; Pantaleo, M. A.; Hrelia, P.; Angelini, S. Personalized medicine in gastrointestinal stromal tumor (GIST): Clinical implications of the somatic and germline DNA analysis Int. J. Mol. Sci. 2015, 16, 15592-15608 10.3390/ijms160715592
37. Fallahi, P.; Ferrari, S. M.; Antonelli, A.; Di Bari, F.; Benvenga, S.; Spisni, R.; Materazzi, G.; Miccoli, P. Selective use of vandetanib in the treatment of thyroid cancer Drug Des., Dev. Ther. 2015, 9, 3459-3470 10.2147/DDDT.S72495
38. Lacouture, M. E.; Wu, S.; Robert, C.; Atkins, M. B.; Kong, H. H.; Guitart, J.; Garbe, C.; Hauschild, A.; Puzanov, I.; Alexandrescu, D. T.; Anderson, R. T.; Wood, L.; Dutcher, J. P. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib Oncologist 2008, 13, 1001-1011 10.1634/theoncologist.2008-0131
39. Ellis, L. M.; Hicklin, D. J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy Clin. Cancer Res. 2008, 14, 6371-6375 10.1158/1078-0432.CCR-07-5287
40. Ding, C.; Zhang, C.; Zhang, M.; Chen, Y. Z.; Tan, C.; Tan, Y.; Jiang, Y. Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2 Future Med. Chem. 2014, 6, 1771-1789 10.4155/fmc.14.112
41. Boulay, A.; Breuleux, M.; Stephan, C.; Fux, C.; Brisken, C.; Fiche, M.; Wartmann, M.; Stumm, M.; Lane, H. A.; Hynes, N. E. The Ret receptor tyrosine kinase pathway functionally interacts with the ERα pathway in breast cancer Cancer Res. 2008, 68, 3743-3751 10.1158/0008-5472.CAN-07-5100
42. Ferretti, S.; Allegrini, P. R.; O'Reilly, T.; Schnell, C.; Stumm, M.; Wartmann, M.; Wood, J.; McSheehy, P. M. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure Clin. Cancer Res. 2005, 11, 7773-7784 10.1158/1078-0432.CCR-05-1165